Journal article
The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer
Abstract
Background: Liquid biopsy (LB) can detect actionable genomic alterations in plasma circulating tumor circulating tumor DNA beyond tissue testing (TT) alone in advanced non-small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of adding LB to TT in the Canadian healthcare system.
Methods: A cost-effectiveness analysis was conducted using a decision analytic Markov model from the Canadian public payer (Ontario) perspective …
Authors
Ezeife DA; Spackman E; Juergens RA; Laskin JJ; Agulnik JS; Hao D; Laurie SA; Law JH; Le LW; Kiedrowski LA
Journal
Therapeutic Advances in Medical Oncology, Vol. 14, ,
Publisher
SAGE Publications
Publication Date
January 2022
DOI
10.1177/17588359221112696
ISSN
1758-8340